MENLO PARK, Calif.--(BUSINESS WIRE)--A key distributor of IncellDx's revolutionary cervical cancer test has signed a definitive agreement to expand the use of HPV OncoTect® within one of Europe's largest clinical laboratory networks. The agreement between distributor LABEC Pharma and the Labco system specifies that Labco will now offer IncellDx’s HPV OncoTect® assay throughout its entire network in Europe. Labco had been offering HPV OncoTect® on a limited basis since mid-2010.